Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRDN 001

Drug Profile

VRDN 001

Alternative Names: Anti-IGF1R monoclonal antibody - Viridian Therapeutics; AVE 1642; VRDN-001; ZB 001

Latest Information Update: 22 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Developer sanofi-aventis; Viridian Therapeutics
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graves ophthalmopathy
  • Discontinued Breast cancer; Multiple myeloma; Solid tumours

Most Recent Events

  • 15 Sep 2022 Zenas BioPharma plans a phase I trial in healthy Chinese volunteers (IV, Injection) (In adults) in China in September 2022 (NCT05542303)
  • 15 Aug 2022 Viridian Therapeutics announces intention to submit BLA for Graves ophthalmopathy in the US
  • 15 Aug 2022 Viridian Therapeutics announces intention to submit MAA to regulatory body for Graves ophthalmopathy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top